SYNAIRGEN PLC — AGM Information 2015

May 15, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3160N

Synairgen plc

15 May 2015

Press release

Synairgen plc

('Synairgen' or the 'Company')

Notice of Annual General Meeting

Southampton, UK - 15 May 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that notice of its 2015 Annual General Meeting ('AGM') has been posted to shareholders and is available on the Company's website, www.synairgen.com. The AGM will be held at 11 a.m. on Monday 22 June 2015 at the offices of Fasken Martineau LLP, 17 Hanover Square, London W1S 1HU.

Ends

For further information, please contact:

Synairgen plc                                                                                     

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

FinnCap                                                                                 

Geoff Nash / James Thompson (Corporate Finance)

Stephen Norcross / Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5701

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOABGGDUGGBBGUU